Alemtuzumab in clinical practice: A British Columbia experience

Leukemia and Lymphoma

Volumn 49, Issue 2, 2008, Pages 218-226

  Hui, David ^a   Lam, Wendy ^b   Toze, Cynthia ^c   Delorme, Michael ^d   Noble, Michael ^e   Klimo, Paul ^f   Sutherland, Judy ^d   Gill, Karamjit ^g   Connors, Joseph ^a   Sehn, Laurie ^a  

^a Vancouver Cancer Centre   (Canada)

^b Ridge Meadows Hospital and Health Care Centre   (Canada)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e ROYAL COLUMBIAN HOSPITAL   (Canada)

^f LIONS GATE HOSPITAL   (Canada)

^g Fraser Valley Cancer Centre   (Canada)

Author keywords

Alemtuzumab; Chronic lymphocytic leukemia; Monoclonal antibody; Targeted therapy

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; COTRIMOXAZOLE; DIMENHYDRINATE; FAMCICLOVIR; FLUCONAZOLE; FLUDARABINE; GANCICLOVIR; HYDROCORTISONE; PARACETAMOL; PETHIDINE; VALACICLOVIR;

ADULT; AGED; ANEMIA; ARTICLE; BACTERIAL INFECTION; CANADA; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL PRACTICE; CYTOMEGALOVIRUS INFECTION; DEMOGRAPHY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; EXPERIENCE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; INJECTION SITE REACTION; LYMPHOPROLIFERATIVE DISEASE; MALE; MONOTHERAPY; MYCOBACTERIUM INTRACELLULARE AVIUM; MYCOSIS FUNGOIDES; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; VIRUS REACTIVATION;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; BRITISH COLUMBIA; DRUG EVALUATION; FEMALE; HUMANS; INFECTION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; NEUTROPENIA; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 38849131246     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701760029     Document Type: Article

References (25)

1. Ravandi, F. and O'Brien, S. (2005) Alemtuzumab. Expert Rev Anticancer Ther, 5, pp. 39-51.
2. Moreton, P. and Hillmen, P. (2003) Alemtuzumab therapy in B-cell lymphoproliferative disorders. Semin Oncol, 30, pp. 493-501.
3. Dearden, C. (2006) The role of alemtuzumab in the management of T-cell malignancies. Semin Oncol, 33, pp. S44-S52.
4. Giralt, S. (2006) The role of alemtuzumab in nonmyeloablative hematopoietic transplantation. Semin Oncol, 33, pp. S36-S43.
5. Osterborg, A., Fassas, A. S., Anagnostopoulos, A., Dyer, M. J., Catovsky, D. and Mellstedt, H. (1996) Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol, 93, pp. 151-153.
6. Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P. A., Celsing, F. and Hjalmar, V. (2002) Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood, 100, pp. 768-773.
7. Osterborg, A., Dyer, M. J., Bunjes, D., Pangalis, G. A., Bastion, Y. and Catovsky, D. (1997) Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol, 15, pp. 1567-1574.
8. Rai, K. R., Freter, C. E., Mercier, R. J., Cooper, M. R., Mitchell, B. S. and Stadtmauer, E. A. (2002) Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol, 20, pp. 3891-3897.
9. Keating, M. J., Flinn, I., Jain, V., Binet, J. L., Hillmen, P. and Byrd, J. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood, 99, pp. 3554-3561.
10. Osterborg, A., Karlsson, C., Lundin, J., Kimby, E. and Mellstedt, H. (2006) Strategies in the management of alemtuzumab-related side effects. Semin Oncol, 33, pp. S29-S35.
11. Fiegl, M., Falkner, A., Hopfinger, G., Brugger, S., Zabernigg, A. and Bauer, F. (2006) Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: A nation-wide retrospective study in Austria. Cancer, 107, pp. 2408-2416.
12. Cheson, B. D., Bennett, J. M., Grever, M., Kay, N., Keating, M. J. and O'Brien, S. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood, 87, pp. 4990-4997.
13. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17, p. 1244.
14. Trotti, A., Colevas, A. D., Setser, A., Rusch, V., Jaques, D. and Budach, V. (2003) CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 13, pp. 176-181.
15. Kaplan, E. L. and Meier, P. (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, pp. 457-481.
16. Mantel, N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep, 50, pp. 163-170.
17. Montserrat, E., Moreno, C., Esteve, J., Urbano-Ispizua, A., Gine, E. and Bosch, F. (2006) How I treat refractory CLL. Blood, 107, pp. 1276-1283.
18. McCune, S. L., Gockerman, J. P., Moore, J. O., Decastro, C. M., Bass, A. J. and Chao, N. J. (2002) Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma, 43, pp. 1007-1011.
19. Rai, K. R., Keating, M. J., Coutre, S., Rizzieri, D. A. and on behalf of the Campath-1H Study Group (2002) Patients with refractory B-CLL and T-PLL treated with alemtuzumab (CamPath) on a compassionate basis. A report on efficacy and safety of CAM 511 trial. Blood, 100, p. 802a.
20. Keating, M. J., O'Brien, S., Kontoyiannis, D., Plunkett, W., Koller, C. and Beran, M. (2002) Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma, 43, pp. 1755-1762.
21. Capalbo, S., Delia, M., Dargenio, M., Liso, A., Diomede, D. and Garofalo, L. (2003) Mycosis fungoides/Sezary syndrome: A report of three cases treated with Campath-1H as salvage treatment. Med Oncol, 20, pp. 389-396.
22. Lundin, J., Osterborg, A., Brittinger, G., Crowther, D., Dombret, H. and Engert, A. (1998) CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol, 16, pp. 3257-3263.
23. Lenihan, D. J., Alencar, A. J., Yang, D., Kurzrock, R., Keating, M. J. and Duvic, M. (2004) Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood, 104, pp. 655-658.
24. Lundin, J., Kennedy, B., Dearden, C., Dyer, M. J. and Osterborg, A. (2005) No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome. Blood, 105, pp. 4148-4149.
25. Ferrajoli, A., O'Brien, S. M., Cortes, J. E., Giles, F. J., Thomas, D. A. and Faderl, S. (2003) Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer, 98, pp. 773-778.